natgillin/translations-raw huggingface dataset:
Additional information on individual components: in addition to the adverse reactions listed above for the combination product, other adverse events previously reported with one of the individual components may be potential adverse events with Irbesartan Hydrochlorothiazide Winthrop.
Dodatni podatki o posameznih učinkovinah: poleg zgoraj naštetih neželenih učinkov, ki se lahko pojavijo med uporabo kombiniranega zdravila, se utegnejo med jemanjem zdravila Irbesartan Hydrochlorothiazide Winthrop pojaviti tudi neželeni učinki o katerih so predhodno poročali pri jemanju posamezne zdravilne učinkovine.
8 Irbesartan:
8 Irbesartan:
Adverse reactions reported with the use of irbesartan alone include:
Med uporabo irbesartana samega so poročali o naslednjih neželenih reakcijah:
Uncommon:
Splošne težave in spremembe na mestu aplikacije: občasni: bolečine v prsih
9 The dose dependent adverse events of hydrochlorothiazide (particularly electrolyte disturbances) may increase when titrating the hydrochlorothiazide.
4. 9 Preveliko odmerjanje
No specific information is available on the treatment of overdose with Irbesartan Hydrochlorothiazide Winthrop.
O zdravljenju posledic prevelikega odmerjanja zdravila Irbesartan Hydrochlorothiazide Winthrop ni specifičnih podatkov.
Irbesartan Hydrochlorothiazide Winthrop is a combination of an angiotensin-II receptor antagonist, irbesartan, and a thiazide diuretic, hydrochlorothiazide.
Zdravilo Irbesartan Hydrochlorothiazide Winthrop je kombinacija irbesartana, antagonista angiotenzina II, in tiazidnega diuretika hidroklorotiazida.
10 The combination of hydrochlorothiazide and irbesartan produces dose-related additive reductions in blood pressure across their therapeutic dose ranges.
Kombinacija hidroklorotiazida in irbesartana povzroči od odmerka odvisno aditivno znižanje krvnega tlaka znotraj terapevtskega intervala.
The addition of 12.5 mg hydrochlorothiazide to 300 mg irbesartan once daily in patients not adequately controlled on 300 mg irbesartan alone resulted in further placebo-corrected diastolic blood pressure reductions at trough (24 hours post-dosing) of 6.1 mm Hg.
10 300 mg irbesartana ni bilo dovolj učinkovito in so začeli jemati tudi po 12, 5 mg hidroklorotiazida enkrat na dan, 24 ur po zaužitju odmerka znižal za povprečno 6, 1 mmHg bolj kot po uporabi placeba.
When measured by ambulatory blood pressure monitoring, the trough to peak effects of Irbesartan Hydrochlorothiazide Winthrop 150 mg/ 12.5 mg were 100%.
Med 24- urnim merjenjem krvnega tlaka pri bolnikih, ki so prejemali zdravilo Irbesartan Hydrochlorothiazide Winthrop 150 mg/ 12, 5 mg, je bilo razmerje med najmanjšim in največjim učinkom 100%.
The trough to peak effects measured by cuff during office visits were 68% and 76% for Irbesartan Hydrochlorothiazide Winthrop 150 mg/ 12.5 mg and Irbesartan Hydrochlorothiazide Winthrop 300 mg/ 12.5 mg, respectively.
Pri merjenju z manšeto v ambulanti je bilo pri bolnikih, ki so jemali zdravilo Irbesartan Hydrochlorothiazide Winthrop 150 mg/ 12, 5 mg, to razmerje 68%, pri tistih, ki so dobivali zdravilo Irbesartan Hydrochlorothiazide Winthrop 300 mg/ 12, 5 mg, pa 76%.
Although not specifically studied with the Irbesartan Hydrochlorothiazide Winthrop, rebound hypertension has not been seen with either irbesartan or hydrochlorothiazide.
Posebnih študij z zdravilom Irbesartan Hydrochlorothiazide Winthrop ni, kljub temu pa povratnega zvišanja krvnega tlaka pri bolnikih, ki so jemali bodisi irbesartan bodisi hidroklorotiazid, po prenehanju jemanja zdravila niso opazili.
There is no difference in response to Irbesartan Hydrochlorothiazide Winthrop, regardless of age or gender.
Odziv na zdravljenje z zdravilom Irbesartan Hydrochlorothiazide Winthrop ni odvisen od starosti ali spola.
Efficacy and safety of Irbesartan Hydrochlorothiazide Winthrop as initial therapy for severe hypertension (defined as SeDBP ≥ 110 mmHg) was evaluated in a multicenter, randomized, double- blind, active-controlled, 8-week, parallel-arm study.
Učinkovitost in varnost zdravila Irbesartan Hydrochlorothiazide Winthrop kot začetnega zdravila za zdravljenje hude hipertenzije (definirana kot diastolični tlak v sedečem položaju (SeDBP) ≥ 110 mmHg) sta bili ovrednoteni z multicentrično, randomizirano, dvojno slepo, z učinkovino nadzorovano, 8- tedensko študijo paralelnih skupin.
A total of 697 patients were randomized in a 2:1 ratio to either irbesartan/ hydrochlorothiazide 150 mg/ 12.5 mg or to irbesartan 150 mg and systematically force-titrated (before assessing the response to the lower dose) after one week to irbesartan/ hydrochlorothiazide 300 mg/ 25 mg or irbesartan 300 mg, respectively.
Po enem tednu zdravljenja so odmerek sistematično povečali (pred ovrednotenjem odziva na nižji odmerek) na irbesartan/ hidroklorotiazid 300 mg/ 25 mg oziroma irbesartan 300 mg.
11 The primary objective of this study was to compare the proportion of patients whose SeDBP was controlled (SeDBP < 90 mmHg) at Week 5 of treatment.
11 Primarni cilj te študije je bil primerjati odstotek bolnikov z nadzorovano vrednostjo diastoličnega tlaka v sedečem položaju (SeDBP < 90 mmHg) v 5. tednu zdravljenja.
Forty-seven percent (47.2%) of patients on the combination achieved trough SeDBP < 90 mmHg compared to 33.2% of patients on irbesartan (p = 0.0005).
Vrednost SeDBP < 90 mmHg je bila dosežena pri sedeminštiridesetih odstotkih (47, 2%) bolnikov, ki so se zdravili s kombinacijo in 33, 2% bolnikov, ki so se zdravili z irbesartanom (p = 0, 0005).
Following oral administration of Irbesartan Hydrochlorothiazide Winthrop, the absolute oral bioavailability is 60-80% and 50-80% for irbesartan and hydrochlorothiazide, respectively.
Po peroralnem jemanju zdravila Irbesartan Hydrochlorothiazide Winthrop je biološka uporabnost irbesartana približno 60- 80%, hidroklorotiazida pa 50- 80%.
Food does not affect the bioavailability of Irbesartan Hydrochlorothiazide Winthrop.
Sočasno uživanje hrane na biološko uporabnost zdravila Irbesartan Hydrochlorothiazide Winthrop ne vpliva.
Irbesartan is not removed by
Irbesartan se s hemodializo ne odstrani iz organizma.
In patients with creatinine clearance < 20 ml/ min, the elimination half-life of hydrochlorothiazide was reported to increase to 21 hours.
12 Jetrna okvara: pri bolnikih z blago do zmerno cirozo farmakokinetični parametri irbesartana niso bistveno spremenjeni.
Animal studies with irbesartan showed transient toxic effects (increased renal pelvic cavitation, hydroureter or subcutaneous oedema) in rat foetuses, which were resolved after birth.
Pri kuncih je prišlo do abortusa ali zgodnje absorpcije pri odmerkih, ki so povzročili pomembno toksičnost pri samici, vključno s smrtjo.
In rabbits,
Teratogenih učinkov pri podganah ali kuncih niso opazili.
13 abortion or early resorption was noted at doses causing significant maternal toxicity, including mortality.
13 Hidroklorotiazid: na nekaj eksperimentalnih modelih so opazili genotoksično in karcinogeno delovanje hidroklorotiazida, vendar pa dokazi niso zanesljivi.
No teratogenic effects were observed in the rat or rabbit.
Hkrati pa tudi izkušnje z uporabo hidroklorotiazida pri ljudeh niso potrdile povezanosti med tem zdravilom in pogostejšim pojavom neoplazem.
Irbesartan Hydrochlorothiazide Winthrop 300 mg/ 12.5 mg tablets.
Irbesartan Hydrochlorothiazide Winthrop 300 mg/ 12, 5 mg tablete
16 Intravascular volume depletion: volume and/ or sodium depletion should be corrected prior to administration of Irbesartan Hydrochlorothiazide Winthrop.
16 Zmanjšan intravaskularni volumen: zmanjšan intravaskularni volumen ali pomanjkanje natrija je treba popraviti pred začetkom uporabe zdravila Irbesartan Hydrochlorothiazide Winthrop.
18 Pregnancy:
18 Nosečnost:
19 extent by glucuronidation.
19 preko CYP2C9.
20 AIIRAs therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy.
20 varnostnim profilom za uporabo v nosečnosti; razen če se oceni, da je nadaljnje zdravljenje z antagonisti angiotenzina II nujno.
21
21 Bolezni prebavil: pogosti: občasni:
22 Irbesartan:
22 Irbesartan:
23 The dose dependent adverse events of hydrochlorothiazide (particularly electrolyte disturbances) may increase when titrating the hydrochlorothiazide.
23 Neželeni učinki hidroklorotiazida, ki so odvisni od odmerka (zlasti elektrolitske motnje), se lahko med titriranjem hidroklorotiazida povečajo.
24 The combination of hydrochlorothiazide and irbesartan produces dose-related additive reductions in blood pressure across their therapeutic dose ranges.
Kombinacija hidroklorotiazida in irbesartana povzroči od odmerka odvisno aditivno znižanje krvnega tlaka znotraj terapevtskega intervala.
The addition of 12.5 mg hydrochlorothiazide to 300 mg irbesartan once daily in patients not adequately controlled on 300 mg irbesartan alone resulted in further placebo-corrected diastolic blood pressure reductions at trough (24 hours post-dosing) of 6.1 mm Hg.
24 300 mg irbesartana ni bilo dovolj učinkovito in so začeli jemati tudi po 12, 5 mg hidroklorotiazida enkrat na dan, 24 ur po zaužitju odmerka znižal za povprečno 6, 1 mmHg bolj kot po uporabi placeba.
25 The primary objective of this study was to compare the proportion of patients whose SeDBP was controlled (SeDBP < 90 mmHg) at Week 5 of treatment.
25 Primarni cilj te študije je bil primerjati odstotek bolnikov z nadzorovano vrednostjo diastoličnega tlaka v sedečem položaju (SeDBP < 90 mmHg) v 5. tednu zdravljenja.
In patients with creatinine clearance < 20 ml/ min, the elimination half-life of hydrochlorothiazide was reported to increase to 21 hours.
26 Jetrna okvara: pri bolnikih z blago do zmerno cirozo farmakokinetični parametri irbesartana niso bistveno spremenjeni.
27 abortion or early resorption was noted at doses causing significant maternal toxicity, including mortality.
27 Hidroklorotiazid: na nekaj eksperimentalnih modelih so opazili genotoksično in karcinogeno delovanje hidroklorotiazida, vendar pa dokazi niso zanesljivi.
Irbesartan Hydrochlorothiazide Winthrop 150 mg/ 12.5 mg film-coated tablets.
Irbesartan Hydrochlorothiazide Winthrop 150 mg/ 12, 5 mg filmsko obložene tablete
30 Intravascular volume depletion: volume and/ or sodium depletion should be corrected prior to administration of Irbesartan Hydrochlorothiazide Winthrop.
30 Zmanjšan intravaskularni volumen: zmanjšan intravaskularni volumen ali pomanjkanje natrija je treba popraviti pred začetkom uporabe zdravila Irbesartan Hydrochlorothiazide Winthrop.
32 Pregnancy:
32 Nosečnost:
33 extent by glucuronidation.
33 preko CYP2C9.
34 AIIRAs therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy.
34 varnostnim profilom za uporabo v nosečnosti; razen če se oceni, da je nadaljnje zdravljenje z antagonisti angiotenzina II nujno.
35
35 Bolezni prebavil: pogosti: občasni:
36 Irbesartan:
36 Irbesartan:
37 The dose dependent adverse events of hydrochlorothiazide (particularly electrolyte disturbances) may increase when titrating the hydrochlorothiazide.
37 Neželeni učinki hidroklorotiazida, ki so odvisni od odmerka (zlasti elektrolitske motnje), se lahko med titriranjem hidroklorotiazida povečajo.
38 The combination of hydrochlorothiazide and irbesartan produces dose-related additive reductions in blood pressure across their therapeutic dose ranges.
Kombinacija hidroklorotiazida in irbesartana povzroči od odmerka odvisno aditivno znižanje krvnega tlaka znotraj terapevtskega intervala.
The addition of 12.5 mg hydrochlorothiazide to 300 mg irbesartan once daily in patients not adequately controlled on 300 mg irbesartan alone resulted in further placebo-corrected diastolic blood pressure reductions at trough (24 hours post-dosing) of 6.1 mm Hg.
38 300 mg irbesartana ni bilo dovolj učinkovito in so začeli jemati tudi po 12, 5 mg hidroklorotiazida enkrat na dan, 24 ur po zaužitju odmerka znižal za povprečno 6, 1 mmHg bolj kot po uporabi placeba.
39 The primary objective of this study was to compare the proportion of patients whose SeDBP was controlled (SeDBP < 90 mmHg) at Week 5 of treatment.
39 Primarni cilj te študije je bil primerjati odstotek bolnikov z nadzorovano vrednostjo diastoličnega tlaka v sedečem položaju (SeDBP < 90 mmHg) v 5. tednu zdravljenja.
In patients with creatinine clearance < 20 ml/ min, the elimination half-life of hydrochlorothiazide was reported to increase to 21 hours.
40 Jetrna okvara: pri bolnikih z blago do zmerno cirozo farmakokinetični parametri irbesartana niso bistveno spremenjeni.
41 abortion or early resorption was noted at doses causing significant maternal toxicity, including mortality.
41 Hidroklorotiazid: na nekaj eksperimentalnih modelih so opazili genotoksično in karcinogeno delovanje hidroklorotiazida, vendar pa dokazi niso zanesljivi.
42 6.6 Special precautions for disposal
42 6. 6 Posebni varnostni ukrepi za odstranjevanje
Irbesartan Hydrochlorothiazide Winthrop 300 mg/ 12.5 mg film-coated tablets.
Irbesartan Hydrochlorothiazide Winthrop 300 mg/ 12, 5 mg filmsko obložene tablete
44 Intravascular volume depletion: volume and/ or sodium depletion should be corrected prior to administration of Irbesartan Hydrochlorothiazide Winthrop.
44 Zmanjšan intravaskularni volumen: zmanjšan intravaskularni volumen ali pomanjkanje natrija je treba popraviti pred začetkom uporabe zdravila Irbesartan Hydrochlorothiazide Winthrop.
46 Pregnancy:
46 Nosečnost:
47 extent by glucuronidation.
47 preko CYP2C9.
48 AIIRAs therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy.
48 varnostnim profilom za uporabo v nosečnosti; razen če se oceni, da je nadaljnje zdravljenje z antagonisti angiotenzina II nujno.
49
49 Bolezni prebavil: pogosti: občasni:
50 Irbesartan:
50 Irbesartan:
51 The dose dependent adverse events of hydrochlorothiazide (particularly electrolyte disturbances) may increase when titrating the hydrochlorothiazide.
51 Neželeni učinki hidroklorotiazida, ki so odvisni od odmerka (zlasti elektrolitske motnje), se lahko med titriranjem hidroklorotiazida povečajo.
52 The combination of hydrochlorothiazide and irbesartan produces dose-related additive reductions in blood pressure across their therapeutic dose ranges.
Kombinacija hidroklorotiazida in irbesartana povzroči od odmerka odvisno aditivno znižanje krvnega tlaka znotraj terapevtskega intervala.
The addition of 12.5 mg hydrochlorothiazide to 300 mg irbesartan once daily in patients not adequately controlled on 300 mg irbesartan alone resulted in further placebo-corrected diastolic blood pressure reductions at trough (24 hours post-dosing) of 6.1 mm Hg.
52 300 mg irbesartana ni bilo dovolj učinkovito in so začeli jemati tudi po 12, 5 mg hidroklorotiazida enkrat na dan, 24 ur po zaužitju odmerka znižal za povprečno 6, 1 mmHg bolj kot po uporabi placeba.
53 The primary objective of this study was to compare the proportion of patients whose SeDBP was controlled (SeDBP < 90 mmHg) at Week 5 of treatment.
53 Primarni cilj te študije je bil primerjati odstotek bolnikov z nadzorovano vrednostjo diastoličnega tlaka v sedečem položaju (SeDBP < 90 mmHg) v 5. tednu zdravljenja.
In patients with creatinine clearance < 20 ml/ min, the elimination half-life of hydrochlorothiazide was reported to increase to 21 hours.
54 Jetrna okvara: pri bolnikih z blago do zmerno cirozo farmakokinetični parametri irbesartana niso bistveno spremenjeni.
55 abortion or early resorption was noted at doses causing significant maternal toxicity, including mortality.
55 Hidroklorotiazid: na nekaj eksperimentalnih modelih so opazili genotoksično in karcinogeno delovanje hidroklorotiazida, vendar pa dokazi niso zanesljivi.
56 6.6 Special precautions for disposal
56 6. 6 Posebni varnostni ukrepi za odstranjevanje
Irbesartan Hydrochlorothiazide Winthrop 300 mg/ 25 mg film-coated tablets.
Irbesartan Hydrochlorothiazide Winthrop 300 mg/ 25 mg filmsko obložene tablete
58 Intravascular volume depletion: volume and/ or sodium depletion should be corrected prior to administration of Irbesartan Hydrochlorothiazide Winthrop.
58 Zmanjšan intravaskularni volumen: zmanjšan intravaskularni volumen ali pomanjkanje natrija je treba popraviti pred začetkom uporabe zdravila Irbesartan Hydrochlorothiazide Winthrop.
60 Pregnancy:
60 Nosečnost:
61 extent by glucuronidation.
61 preko CYP2C9.
62 AIIRAs therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy.
62 varnostnim profilom za uporabo v nosečnosti; razen če se oceni, da je nadaljnje zdravljenje z antagonisti angiotenzina II nujno.
63
63 Bolezni prebavil: pogosti: občasni:
64 Irbesartan:
64 Irbesartan:
65 The dose dependent adverse events of hydrochlorothiazide (particularly electrolyte disturbances) may increase when titrating the hydrochlorothiazide.
65 Neželeni učinki hidroklorotiazida, ki so odvisni od odmerka (zlasti elektrolitske motnje), se lahko med titriranjem hidroklorotiazida povečajo.
66 The combination of hydrochlorothiazide and irbesartan produces dose-related additive reductions in blood pressure across their therapeutic dose ranges.
Kombinacija hidroklorotiazida in irbesartana povzroči od odmerka odvisno aditivno znižanje krvnega tlaka znotraj terapevtskega intervala.
The addition of 12.5 mg hydrochlorothiazide to 300 mg irbesartan once daily in patients not adequately controlled on 300 mg irbesartan alone resulted in further placebo-corrected diastolic blood pressure reductions at trough (24 hours post-dosing) of 6.1 mm Hg.
66 300 mg irbesartana ni bilo dovolj učinkovito in so začeli jemati tudi po 12, 5 mg hidroklorotiazida enkrat na dan, 24 ur po zaužitju odmerka znižal za povprečno 6, 1 mmHg bolj kot po uporabi placeba.
67 The primary objective of this study was to compare the proportion of patients whose SeDBP was controlled (SeDBP < 90 mmHg) at Week 5 of treatment.
67 Primarni cilj te študije je bil primerjati odstotek bolnikov z nadzorovano vrednostjo diastoličnega tlaka v sedečem položaju (SeDBP < 90 mmHg) v 5. tednu zdravljenja.
In patients with creatinine clearance < 20 ml/ min, the elimination half-life of hydrochlorothiazide was reported to increase to 21 hours.
68 Jetrna okvara: pri bolnikih z blago do zmerno cirozo farmakokinetični parametri irbesartana niso bistveno spremenjeni.
69 abortion or early resorption was noted at doses causing significant maternal toxicity, including mortality.
69 Hidroklorotiazid: na nekaj eksperimentalnih modelih so opazili genotoksično in karcinogeno delovanje hidroklorotiazida, vendar pa dokazi niso zanesljivi.
The PSUR cycle of Irbesartan Hydrochlorothiazide Winthrop is aligned with the cross-referred product, COAPROVEL, until otherwise specified.
Cikel predajanja periodičnih poročil o varnosti zdravila Irbesartan Hydrochlorothiazide Winthrop, je vezan na referenčno zdravilo COAPROVEL, dokler ni določeno drugače.
Irbesartan Hydrochlorothiazide Winthrop 150 mg/ 12.5 mg tablets irbesartan/ hydrochlorothiazide
Irbesartan Hydrochlorothiazide Winthrop 150 mg/ 12, 5 mg tablete irbesartan/ hidroklorotiazid
EU/ 1/ 06/ 377/ 001 14 tablets EU/ 1/ 06/ 377/ 002 28 tablets EU/ 1/ 06/ 377/ 003 56 tablets EU/ 1/ 06/ 377/ 004 56 x 1 tablets EU/ 1/ 06/ 377/ 005 98 tablets
EU/ 1/ 06/ 377/ 001 14 tablet EU/ 1/ 06/ 377/ 002 28 tablet EU/ 1/ 06/ 377/ 003 56 tablet EU/ 1/ 06/ 377/ 004 56 x 1 tableta EU/ 1/ 06/ 377/ 005 98 tablet
Irbesartan Hydrochlorothiazide Winthrop 300 mg/ 12.5 mg tablets irbesartan/ hydrochlorothiazide
Irbesartan Hydrochlorothiazide Winthrop 300 mg/ 12, 5 mg tablete irbesartan/ hidroklorotiazid
EU/ 1/ 06/ 377/ 006 14 tablets EU/ 1/ 06/ 377/ 007 28 tablets EU/ 1/ 06/ 377/ 008 56 tablets EU/ 1/ 06/ 377/ 009 56 x 1 tablets EU/ 1/ 06/ 377/ 010 98 tablets
EU/ 1/ 06/ 377/ 006 14 tablet EU/ 1/ 06/ 377/ 007 28 tablet EU/ 1/ 06/ 377/ 008 56 tablet EU/ 1/ 06/ 377/ 009 56 x 1 tableta EU/ 1/ 06/ 377/ 010 98 tablet
Irbesartan Hydrochlorothiazide Winthrop 150 mg/ 12.5 mg film-coated tablets irbesartan/ hydrochlorothiazide
Irbesartan Hydrochlorothiazide Winthrop 150 mg/ 12, 5 mg filmsko obložene tablete irbesartan/ hidroklorotiazid
EU/ 1/ 06/ 377/ 011 14 tablets EU/ 1/ 06/ 377/ 012 28 tablets EU/ 1/ 06/ 377/ 013 56 tablets EU/ 1/ 06/ 377/ 014 56 x 1 tablets EU/ 1/ 06/ 377/ 015 84 tablets EU/ 1/ 06/ 377/ 016 98 tablets
EU/ 1/ 06/ 377/ 011 14 tablet EU/ 1/ 06/ 377/ 012 28 tablet EU/ 1/ 06/ 377/ 013 56 tablet EU/ 1/ 06/ 377/ 014 56 x 1 tableta EU/ 1/ 06/ 377/ 015 84 tablet EU/ 1/ 06/ 377/ 016 98 tablet
Irbesartan Hydrochlorothiazide Winthrop 300 mg/ 12.5 mg film-coated tablets irbesartan/ hydrochlorothiazide
Irbesartan Hydrochlorothiazide Winthrop 300 mg/ 12, 5 mg filmsko obložene tablete irbesartan/ hidroklorotiazid
EU/ 1/ 06/ 377/ 017 14 tablets EU/ 1/ 06/ 377/ 018 28 tablets EU/ 1/ 06/ 377/ 019 56 tablets EU/ 1/ 06/ 377/ 020 56 x 1 tablets EU/ 1/ 06/ 377/ 021 84 tablets EU/ 1/ 06/ 377/ 022 98 tablets
EU/ 1/ 06/ 377/ 017 14 tablet EU/ 1/ 06/ 377/ 018 28 tablet EU/ 1/ 06/ 377/ 019 56 tablet EU/ 1/ 06/ 377/ 020 56 x 1 tableta EU/ 1/ 06/ 377/ 021 84 tablet EU/ 1/ 06/ 377/ 022 98 tablet
Irbesartan Hydrochlorothiazide Winthrop 300 mg/ 25 mg film-coated tablets irbesartan/ hydrochlorothiazide
Irbesartan Hydrochlorothiazide Winthrop 300 mg/ 25 mg filmsko obložene tablete irbesartan/ hidroklorotiazid
EU/ 1/ 06/ 377/ 023 14 tablets EU/ 1/ 06/ 377/ 024 28 tablets EU/ 1/ 06/ 377/ 025 56 tablets EU/ 1/ 06/ 377/ 026 56 x 1 tablets EU/ 1/ 06/ 377/ 027 84 tablets EU/ 1/ 06/ 377/ 028 98 tablets
EU/ 1/ 06/ 377/ 023 14 tablet EU/ 1/ 06/ 377/ 024 28 tablet EU/ 1/ 06/ 377/ 025 56 tablet EU/ 1/ 06/ 377/ 026 56 x 1 tableta EU/ 1/ 06/ 377/ 027 84 tablet EU/ 1/ 06/ 377/ 028 98 tablet
Irbesartan Hydrochlorothiazide Winthrop 300 mg/ 25 mg tablets irbesartan/ hydrochlorothiazide
Irbesartan Hydrochlorothiazide Winthrop 300 mg/ 25 mg tablete irbesartan/ hidroklorotiazid
INFORMATION FOR THE USER Irbesartan Hydrochlorothiazide Winthrop 150 mg/ 12.5 mg tablets irbesartan/ hydrochlorothiazide
91 NAVODILO ZA UPORABO Irbesartan Hydrochlorothiazide Winthrop 150 mg/ 12, 5 mg tablete irbesartan/ hidroklorotiazid
What Irbesartan Hydrochlorothiazide Winthrop is and what it is used for 2.
Kaj je zdravilo Irbesartan Hydrochlorothiazide Winthrop in za kaj ga uporabljamo 2.
Before you take Irbesartan Hydrochlorothiazide Winthrop 3.
Kaj morate vedeti, preden boste vzeli zdravilo Irbesartan Hydrochlorothiazide Winthrop 3.
How to take Irbesartan Hydrochlorothiazide Winthrop 4.
Kako jemati zdravilo Irbesartan Hydrochlorothiazide Winthrop 4.
How to store Irbesartan Hydrochlorothiazide Winthrop 6.
Shranjevanje zdravila Irbesartan Hydrochlorothiazide Winthrop 6.
WHAT IRBESARTAN HYDROCHLOROTHIAZIDE WINTHROP IS AND WHAT IT IS USED FOR
KAJ JE ZDRAVILO IRBESARTAN HYDROCHLOROTHIAZIDE WINTHROP IN ZA KAJ GA UPORABLJAMO
Irbesartan Hydrochlorothiazide Winthrop is a combination of two active substances, irbesartan and hydrochlorothiazide.
Zdravilo Irbesartan Hydrochlorothiazide Winthrop je kombinacija dveh zdravilnih učinkovin, irbesartana in hidroklorotiazida.
The two active ingredients in Irbesartan Hydrochlorothiazide Winthrop work together to lower blood pressure further than if either was given alone.
Zdravilni učinkovini v zdravilu Irbesartan Hydrochlorothiazide Winthrop znižujeta krvni tlak, in to še bolj kot če bi jemali vsako učinkovino posebej.
Irbesartan Hydrochlorothiazide Winthrop is used in the treatment of high blood pressure (essential hypertension), when treatment with irbesartan or hydrochlorothiazide alone did not provide adequate control of your blood pressure.
Zdravilo Irbesartan Hydrochlorothiazide Winthrop uporabljamo za zdravljenje zvišanega krvnega tlaka (esencialne hipertenzije), če pri zdravljenju samo z irbesartanom ali samo s hidroklorotiazidom krvni tlak ni bil zadostno nadzorovan.
BEFORE YOU TAKE IRBESARTAN HYDROCHLOROTHIAZIDE WINTHROP
KAJ MORATE VEDETI, PREDEN BOSTE VZELI ZDRAVILO IRBESARTAN HYDROCHLOROTHIAZIDE WINTHROP